Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | STAT1 | P42224 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 3/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21807606 | 1.00 | KDM4E (0.43) | KDM4EMAPTSMN1; SMN2MEN1USP2 | |
| SCHEMBL9899803 | 0.72 | KDM4E (0.45) | KDM4EMAPTSMN1; SMN2MEN1USP2 | |
| SCHEMBL21175952 | 0.69 | ACHE (0.38) | — | |
| SCHEMBL7097279 | 0.66 | KDM4E (0.69) | KDM4EMAPTSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL3144077 | 0.64 | MAPT (0.52) | KDM4EMAPTSMN1; SMN2MEN1USP2 | |
| SCHEMBL85996 | 0.63 | MAOB (0.62) | KDM4EMAPTSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL11790312 | 0.62 | KDM4E (0.49) | KDM4EMAPTSMN1; SMN2MEN1USP2 | |
| SCHEMBL13563997 | 0.61 | KDM4E (0.62) | KDM4EMAPTALDH1A1HPGDHSD17B10 | |
| Dehydrovariabilin SCHEMBL13657398 | 0.61 | MAPT (1.00) | KDM4EMAPTSMN1; SMN2MEN1USP2 | |
| Dehydrovariabilin SCHEMBL31368572 | 0.61 | MAPT (1.00) | KDM4EMAPTSMN1; SMN2MEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377450-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| EP-3852751-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| CN-112955142-A | Functionalized heterocyclic compounds as antiviral agents | 英安塔制药有限公司 | 2021-06-11 | — | — | CN | disclosed |
| US-20210115060-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2021-04-22 | — | — | US | disclosed |
| US-10865211-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| WO-2020061435-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| US-20200095258-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377450-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | KDM4E 1899/4885MAPT 4614/4885SMN1; SMN2 4669/4885 |
| US-10865211-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | KDM4E 1899/4885MAPT 4614/4885SMN1; SMN2 4669/4885 |
| US-20210115060-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | KDM4E 1899/4885MAPT 4614/4885SMN1; SMN2 4669/4885 |
| US-20200095258-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | KDM4E 1899/4885MAPT 4614/4885SMN1; SMN2 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.